Jazz Pharmaceuticals (JAZZ) Misses Q2 EPS by 17c; Issues Mixed Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/19/2024
- Stocks end near flat as investors assess earnings, data
- Netflix Q1 earnings top estimates on blowout subscriber growth
- Taiwan Semi (TSM) Q1 profit beats expectations on AI demand
- Stocks have priced in much of the 2024 optimism - Wells Fargo
- Intuitive Surgiical (ISRG) beats earnings, revenue expectations in Q1
- Tritium DCFC Limited (DCFC): Three Australian subsidiaries were determined to be insolvent or likely to become insolvent
- Hasbro (HAS) Announces Resignation of Cynthia Williams, President of Wizards of the Coast and Hasbro Gaming
- Frontier Communications (FYBR) says third party had gained unauthorized access to portions of its information technology environment
- Ibotta (IBTA) Prices 6.56M Share IPO at $88/sh
- Netflix (NFLX) Tops Q1 EPS by 77c, Offers Guidance
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
- Midday movers: Tesla, Blackstone, Las Vegas Sands fall; DR Horton rises
- After-hours movers: Alcoa rises; Equifax and Las Vegas Sands fall
- Midday movers: Travelers, JB Hunt fall; United Airlines rises
- After-hours movers: United Airlines, J.B. Hunt, and more
Piper Jaffray Cuts Price Target on Jazz Pharmaceuticals (JAZZ) to $178 Following Mixed 2Q
August 10, 2016 8:27 AM EDTPiper Jaffray maintained an Overweight rating on Jazz Pharmaceuticals (NASDAQ: JAZZ), and cut the price target to $178.00 (from $188.00), following the company's 2Q earnings report. JAZZ reported a non-GAAP EPS of $2.63 compared to Street estimates of $2.78. Revenues of $381M, compared to Street estimates of $376M.
Analyst David Amsellem... More
